Alaunos Therapeutics, Inc. (TCRT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98973P3091
Alaunos Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 5,000.00 USD |
| Operating income | -4.23 m USD |
| EBIT | -4.18 m USD |
| Net income | -4.18 m USD |
| Diluted EPS – continuing operations | -2.20 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
More stocks
- Vemanti Group, Inc. (VMNT)
- CHASE PACKAGING CORP (WHLT)
- Fly-E Group, Inc. (FLYE)
- PharmaCyte Biotech, Inc. (PMCB)
- DNA X, Inc. (SONM)
- Abpro Holdings, Inc. (ABPO)
- MAGELLAN COPPER & GOLD Corp (MAGE)
- Global Warming Solutions, Inc. (GWSO)
- Apimeds Pharmaceuticals US, Inc. (APUS)
- GRI Bio, Inc. (GRI)
- Healthcare Triangle, Inc. (HCTI)
- Fathom Holdings Inc. (FTHM)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.